Robeco Institutional Asset Management B.V. Buys 12,750 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Robeco Institutional Asset Management B.V. boosted its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 18.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 82,694 shares of the company's stock after purchasing an additional 12,750 shares during the period. Robeco Institutional Asset Management B.V. owned 0.18% of Pacira BioSciences worth $2,055,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of PCRX. Sterling Capital Management LLC lifted its stake in Pacira BioSciences by 779.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock valued at $26,000 after acquiring an additional 1,208 shares during the last quarter. Ancora Advisors LLC acquired a new stake in Pacira BioSciences in the fourth quarter valued at approximately $26,000. Wealthquest Corp acquired a new stake in Pacira BioSciences in the first quarter valued at approximately $59,000. PNC Financial Services Group Inc. lifted its stake in Pacira BioSciences by 16.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock valued at $68,000 after acquiring an additional 513 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in Pacira BioSciences by 112.8% in the first quarter. GAMMA Investing LLC now owns 3,694 shares of the company's stock valued at $92,000 after acquiring an additional 1,958 shares during the last quarter. Institutional investors and hedge funds own 99.73% of the company's stock.

Insider Transactions at Pacira BioSciences

In related news, SVP Lauren Riker sold 5,578 shares of the business's stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $26.21, for a total transaction of $146,199.38. Following the transaction, the senior vice president owned 59,564 shares of the company's stock, valued at approximately $1,561,172.44. The trade was a 8.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 6.40% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on PCRX. Wall Street Zen upgraded shares of Pacira BioSciences from a "hold" rating to a "buy" rating in a research note on Friday, June 6th. HC Wainwright lifted their target price on shares of Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a research note on Tuesday, April 8th. Finally, Needham & Company LLC reduced their target price on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a research note on Friday, May 9th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, Pacira BioSciences has an average rating of "Hold" and an average target price of $26.44.

Pacira BioSciences Stock Performance

Shares of Pacira BioSciences stock traded down $0.01 on Friday, reaching $23.21. The stock had a trading volume of 202,316 shares, compared to its average volume of 915,165. The business's 50-day moving average price is $25.17 and its two-hundred day moving average price is $24.12. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.99 and a current ratio of 2.41. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $27.64. The stock has a market cap of $1.07 billion, a P/E ratio of -10.18 and a beta of 0.48.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.